These inverse findings imply that we may expect an increased prevalence of HER2 expression in Tanzania and sub-Saharan Africa in general when breast cancer immunostaining becomes routine because of the prevalent hormonal receptor negativity. This evidence concerns the gene ERBB2 and breast carcinoma.